Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
Por:
Álamo MDC, Ochenduszko S, Crespo G, Corral M, Oramas J, Sancho P, Medina J, Garicano F, López P, Campos Balea B, Rodríguez Garzotto A and Muñoz-Couselo E
Publicada:
1 ene 2021
Ahead of Print:
27 nov 2021
Resumen:
Background: The combination of BRAF and MEK inhibitors delays the onset of resistance and provides more sustained and dramatic responses in comparison with a BRAF inhibitor in monotherapy. The objective of the study was to evaluate the effectiveness of the combination therapy with vemurafenib/cobimetinib in terms of durability, and to describe differential characteristics in patients associated to durable responses in real-world settings.
Patients and Methods: Retrospective, observational, cross-sectional, multicenter study involving 41 patients with advanced melanoma harboring a BRAF(v600) mutation who initiated a combination therapy with vemurafenib/cobimetinib between May 2018 and March 2019. Participants were differentiated regarding the durability of the response: durable (complete response, CR, or a partial response, PR, for at least 12 months) and non-durable (stable disease, SD, progressive disease, PD, or CR/PR <12 months). Secondary endpoints included treatment adherence, labor productivity, anxiety/depression, and safety profile.
Results: During the combination therapy, 12 patients (29.3%) had a CR, 19 a PR (46.3%), 5 showed SD (12.2%), and 5 had PD. A total of 12 patients (29.3%) were considered as achieving a durable response and 29 (70.7%) as a non-durable one. Practically all socio-demographic and clinical characteristics were similar between patients. Body mass index was the only differential factor (with higher body mass index achieving a non-durable response). The treatment adherence was 100% in patients with durable response and 66.7% in those with non-durable.
Conclusion: The combination treatment with vemurafenib/cobimetinib results in an important impact on long-term survival, leading to a steady CR in one-third of the patients.
Filiaciones:
Álamo MDC:
Oncology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain
:
Oncology Department, Hospital Universitario Dr. Peset, Valencia, Spain
Crespo G:
Oncology Department, Hospital Universitario de Burgos, Burgos, Spain
Corral M:
Oncology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
Oramas J:
Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
Sancho P:
Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
Medina J:
Oncology Department, Hospital Universitario Virgen de la Salud, Toledo, Spain
Garicano F:
Oncology Department, Hospital de Galdakao, Bizkaia, Spain
López P:
Oncology Department, Complejo Hospitalario General de Jaén, Jaén, Spain
Campos Balea B:
Oncology Department, Hospital Lucus Augusti, Lugo, Spain
Rodríguez Garzotto A:
Medical Department and Strategy, Roche S.A, Madrid, Spain
Muñoz-Couselo E:
Oncology Department, Hospital Universitario Vall d´Hebron, Barcelona, Spain
VHIO Vall d'Hebron Institute on Oncology, Barcelona, Spain
gold, Green Published
FULL TEXT
 |
Published Version |
|
| No Accesible |
|